Welcome to our dedicated page for Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of stock.
Takeda Pharmaceutical Company Limited (NYSE: TAK), a Japanese multinational corporation, stands as Asia's largest and one of the globe's top 20 pharmaceutical giants by revenue. Headquartered in Tokyo, Takeda operates across approximately 80 countries, merging American and British roots into its vast global presence.
With a revenue of JPY 4.3 trillion in fiscal 2023, Takeda dedicates its efforts predominantly to five therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which collectively generate more than 80% of its revenue. Takeda’s global footprint is diversified, with 50% of its revenue originating from the US, 20% from Japan, and another 20% from Europe and Canada.
Noteworthy for its robust pipeline and commitment to innovation, Takeda partners with various organizations to push the boundaries of medical research. A recent highlight includes a joint venture with Astellas Pharma Inc. and Sumitomo Mitsui Banking Corporation. This collaboration aims to incubate early drug discovery programs, striving to transition academic breakthroughs into practical medical treatments.
Moreover, Takeda's strategic partnership with Neurocrine Biosciences to develop NBI-1065845, an investigational treatment for major depressive disorder, showcases its dedication to addressing unmet medical needs. The positive Phase 2 results of the SAVITRI™ study underline the potential of NBI-1065845 to provide hope for patients with inadequate responses to existing treatments.
Takeda's philosophy focuses on creating a healthier world through life-transforming treatments in its core areas. Their values-based, R&D-driven approach has sustained their leadership in the pharmaceutical sector for over two centuries.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) provided a comprehensive update during the 39th Annual J.P. Morgan Healthcare Conference. CEO Christophe Weber highlighted Takeda's strong business resilience amid COVID-19 and outlined plans for revenue growth through an innovative pipeline, targeting JPY5 trillion ($47 billion) by FY2030. Key programs, including TAK-003 for dengue and TAK-755 for thrombotic thrombocytopenic purpura, are expected to contribute significantly to revenue. Takeda aims to maintain investment-grade credit ratings, with a focus on cost synergies and shareholder returns.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is set to participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. The virtual presentation will take place at 5:20 p.m. ET and will feature CEO Christophe Weber. Investors and the public can access the live webcast here. A replay and downloadable slides will also be available on Takeda's website following the event.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has successfully concluded the sale of a non-core portfolio of 16 prescription products to Cheplapharm for $562 million. This divestment, originally announced in September 2020, aligns with Takeda's strategy to streamline its focus on key therapeutic areas including Gastroenterology and Oncology. Proceeds from the sale will be allocated towards reducing debt, aiming for a net debt/adjusted EBITDA ratio of 2x by 2023. Takeda has exceeded its $10 billion divestiture goal with a total of 11 deals worth approximately $11.6 billion since January 2019.
Takeda Pharmaceutical Company has agreed to divest a non-core portfolio of prescription pharmaceutical products in China to Hasten Biopharmaceutic Co., Ltd. for $322 million. This portfolio, which generated approximately $109.5 million in sales during FY2019, includes cardiovascular products like Ebrantil. The divestiture aligns with Takeda's strategy to focus on core therapeutic areas such as Gastroenterology and Oncology. Proceeds will be used to reduce debt and support long-term growth, with over 15 product approvals planned in China over the next five years.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced FDA approval for the supplemental New Drug Application (sNDA) of ICLUSIG® (ponatinib) for adults with chronic-phase chronic myeloid leukemia (CML) who are resistant or intolerant to at least two prior kinase inhibitors. The updated regimen features a starting dose of 45 mg, reducing to 15 mg upon achieving ≤1% BCR-ABL1IS. The approval is based on data from the OPTIC and PACE trials. The revised label is expected to optimize treatment for patients with resistant CML, providing significant clinical benefits.
Prime Therapeutics has secured an agreement with Takeda Pharmaceuticals for its hemophilia A treatment, ADVATE. This collaboration aims to evaluate clinical outcomes and costs associated with hemophilia A treatments, which have become increasingly expensive. The agreement introduces a health plan remuneration model linked to quantifiable medical costs from ineffective treatments under a total cost of care framework. Hemophilia A affects around 80% of the 18,000 people living with the disorder in the U.S., presenting an opportunity for improved patient and cost outcomes.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced that the FDA has accepted its New Drug Application for TAK-721, a treatment for eosinophilic esophagitis (EoE), granting it Priority Review. If approved, TAK-721 will be the first FDA-approved therapy for EoE. The product had previously received Breakthrough Therapy and Orphan Drug designations. The NDA filing is based on successful Phase 3 trials demonstrating its safety and efficacy. EoE affects approximately 1 in 2,000 people in the U.S., leading to significant quality of life impacts due to related symptoms.
Takeda Pharmaceutical Company Limited (TAK) has completed the sale of a portfolio of 18 pharmaceutical and OTC products to Celltrion Inc. for $278 million, including milestone payments. This divestment, part of Takeda's strategy to focus on core areas, is expected to aid in reducing debt and accelerating deleveraging to achieve a net debt/adjusted EBITDA target of 2x by FY 2023. The sale comes after Takeda exceeded its $10 billion non-core asset divestiture target, totaling ~$11.3 billion in agreements since January 2019.
On November 11, 2020, Takeda announced a strategic partnership with OrigiMed to create a genomic-based precision medicine platform. This collaboration aims to enhance R&D and commercialization of innovative medicines in China, addressing unmet medical needs. Takeda plans to introduce over 15 innovative drugs to the Chinese market within five years, benefiting approximately 10 million patients. OrigiMed will leverage its genomic datasets and advanced sequencing technology to support these developments.
FAQ
What is the current stock price of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What is the market cap of Takeda Pharmaceutical Company American Depositary Shares (each representing 1/2 of a share of (TAK)?
What are Takeda Pharmaceutical's core therapeutic areas?
Where is Takeda Pharmaceutical headquartered?
What recent collaborations has Takeda Pharmaceutical entered into?
How diversified is Takeda's revenue geographically?
What was Takeda's revenue in fiscal 2023?
Who can benefit from Takeda's new drug NBI-1065845?
What is the focus of Takeda’s joint venture with Astellas and Sumitomo Mitsui?
How long has Takeda been in the pharmaceutical industry?
In how many countries does Takeda operate?
How does Takeda contribute to the field of major depressive disorder treatment?
